Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Non-Current Deffered Revenue: 2020-2021

Historic Non-Current Deffered Revenue for Cullinan Therapeutics (CGEM) over the last 2 years, with Dec 2021 value amounting to $65,000.

  • Cullinan Therapeutics' Non-Current Deffered Revenue fell 12.16% to $65,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $65,000, marking a year-over-year decrease of 12.16%. This contributed to the annual value of $65,000 for FY2021, which is 12.16% down from last year.
  • According to the latest figures from FY2021, Cullinan Therapeutics' Non-Current Deffered Revenue is $65,000, which was down 12.16% from $74,000 recorded in FY2020.
  • Cullinan Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $74,000 during FY2020, with a 5-year trough of $65,000 in FY2021.
  • Moreover, its 2-year median value for Non-Current Deffered Revenue was $69,500 (2020), whereas its average is $69,500.
  • Data for Cullinan Therapeutics' Non-Current Deffered Revenue shows a maximum YoY dropped of 12.16% (in 2021) over the last 5 years.
  • Yearly analysis of 2 years shows Cullinan Therapeutics' Non-Current Deffered Revenue stood at $74,000 in 2020, then declined by 12.16% to $65,000 in 2021.